Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it will not hold a second quarter 2019 earnings conference call and will not update previously provided financial guidance given the pending acquisition by an affiliate of the Permira funds.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.